Recce Pharmaceuticals Achieves Rapid Dosing Milestone in UTI/Urosepsis Trial

In a Phase I/II UTI/Urosepsis clinical trial, Recce Pharmaceuticals Ltd (ASX:RCE) has achieved a significant milestone with the dosing of the first male and female subjects at a high concentration of RECCE® 327 (R327) at 3,000mg intravenously within just 15 minutes, marking the fastest infusion rate to date.

An independent safety committee confirmed the safety and tolerability of R327 at this rate. The trial is on track to reach its primary endpoints, and this achievement demonstrates the potential for R327 as a first-line treatment for UTI/Urosepsis. Recce Pharmaceuticals is developing a new class of Synthetic Anti-infectives to combat antibiotic-resistant superbugs and emerging viral pathogens.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com